HPV16 Load Is a Potential Biomarker to Predict Risk of High-Grade Cervical Lesions in High-Risk HPV-Infected Women: A Large Longitudinal French Hospital-Based Cohort Study.
HPV16 viral load
cervix
high-grade lesion
prognosis
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
18 Aug 2021
18 Aug 2021
Historique:
received:
15
06
2021
revised:
27
07
2021
accepted:
04
08
2021
entrez:
27
8
2021
pubmed:
28
8
2021
medline:
28
8
2021
Statut:
epublish
Résumé
High-risk HPV (hrHPV) testing has been implemented as a primary screening tool for cervical cancer in numerous countries. However, there is still a need for relevant triage strategies to manage hrHPV positive women to avoid excessive referral to colposcopy. The objective of this study was to assess, in women infected by hrHPV and presenting no or mild cytological abnormalities, HPV16 and HPV18 viral loads to predict the development of cervical high-grade lesion. Among 2102 women positive for hrHPV, 885 had no lesion or mild cytological abnormalities at baseline and had at least one follow-up (FU) visit. HPV16 and HPV18 prevalence was 25.9% and 8.4%, respectively. Of those women, 15% developed a high-grade lesion during the FU. An HPV16 viral load cut-off set at 3.2 log
Identifiants
pubmed: 34439304
pii: cancers13164149
doi: 10.3390/cancers13164149
pmc: PMC8394477
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Papillomavirus Res. 2016 Dec;2:112-115
pubmed: 29074170
Am J Obstet Gynecol. 2013 Mar;208(3):184.e1-184.e11
pubmed: 23174289
JAMA. 2001 Jun 20;285(23):2995-3002
pubmed: 11410098
J Cell Mol Med. 2012 Dec;16(12):3096-104
pubmed: 22978795
J Natl Cancer Inst Monogr. 2003;(31):3-13
pubmed: 12807939
Clin Microbiol Infect. 2020 Sep;26(9):1144-1150
pubmed: 32247892
Am J Clin Pathol. 2011 Oct;136(4):578-86
pubmed: 21917680
Int J Cancer. 2020 May 1;146(9):2599-2607
pubmed: 31490545
Int J Cancer. 2016 Nov 1;139(9):2021-32
pubmed: 27339821
Br J Cancer. 2005 Mar 14;92(5):891-4
pubmed: 15756259
Eur J Cancer. 2004 May;40(8):1225-32
pubmed: 15110887
J Clin Virol. 2006 Mar;35(3):270-7
pubmed: 16214397
Int J Cancer. 2008 Jan 15;122(2):428-32
pubmed: 17893882
Int J Cancer. 2002 Apr 1;98(4):590-5
pubmed: 11920620
Eur J Clin Microbiol Infect Dis. 2012 Sep;31(9):2401-6
pubmed: 22382821
Int J Cancer. 2017 May 15;140(10):2192-2200
pubmed: 28006858
Cochrane Database Syst Rev. 2017 Aug 10;8:CD008587
pubmed: 28796882
Int J Cancer. 2003 Sep 1;106(3):396-403
pubmed: 12845680
Cancer Epidemiol Biomarkers Prev. 2003 Jun;12(6):477-84
pubmed: 12814990
PLoS One. 2019 Jul 26;14(7):e0220200
pubmed: 31348794
J Natl Cancer Inst. 2005 Jul 20;97(14):1072-9
pubmed: 16030305
Lancet Oncol. 2009 Apr;10(4):321-2
pubmed: 19350698
Viruses. 2018 Dec 19;10(12):
pubmed: 30572620
Int J Cancer. 2012 Nov 15;131(10):2349-59
pubmed: 22323075
Br J Cancer. 2019 Nov;121(11):954-965
pubmed: 31616037
N Engl J Med. 2003 Feb 6;348(6):518-27
pubmed: 12571259
J Clin Microbiol. 2015 Jan;53(1):52-9
pubmed: 25339396
Am J Obstet Gynecol. 2003 Jun;188(6):1383-92
pubmed: 12824967
Best Pract Res Clin Obstet Gynaecol. 2018 Feb;47:107-118
pubmed: 28918099
J Virol Methods. 2013 Nov;193(2):498-502
pubmed: 23891872
J Infect Dis. 2011 May 15;203(10):1425-33
pubmed: 21415020
N Engl J Med. 1999 Nov 25;341(22):1633-8
pubmed: 10572150
J Natl Cancer Inst. 2003 Sep 3;95(17):1336-43
pubmed: 12953088
Infect Agent Cancer. 2015 Nov 23;10:43
pubmed: 26600869
J Med Virol. 2012 Feb;84(2):306-13
pubmed: 22170552
J Pathol. 1999 Sep;189(1):12-9
pubmed: 10451482
Lancet Oncol. 2014 Mar;15(3):315-22
pubmed: 24529697
Lancet. 2000 Jun 24;355(9222):2189-93
pubmed: 10881891
PLoS One. 2013 Nov 14;8(11):e79372
pubmed: 24244490
J Med Virol. 2012 Jun;84(6):964-72
pubmed: 22499020